Fractyl Labs raises $44 million in Series D to develop a treatment for type 2 diabetes

Posted by: assetpharmacy December 1, 2017
Fractyl Labs , a Lexington, Massachusetts-based start-up establishing treatments for diabetes, has actually raised $44 million in Series D funding from a multitude of VC companies, consisting of GV, True Ventures, the IDO Fund, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, L.P., and Deerfield...
Read more